阿托伐他汀钙联合依达拉奉对急性脑梗死患者hs-CRP和同型半胱氨酸水平的影响  

The Effect of Atorvastatin Calcium Combined with Edaravone on hs-CRP and Homocysteine Levels in Patients with Acute Cerebral Infarction

作　　者：管海兵[1] 葛胜[1] 沈斌[1] GUAN Hai-bing;GE Sheng;SHEN Bin(Department of Neurology,Qidong People's Hospital,Qidong 226200,Jiangsu,China)

机构地区：[1]启东市人民医院神经内科,江苏启东226200

出　　处：《医学信息》2021年第19期110-112,共3页Journal of Medical Information

摘　　要：目的研究阿托伐他汀钙联合依达拉奉对急性脑梗死患者hs-CRP和同型半胱氨酸(Hcy)水平的影响。方法选取2018年6月-2020年6月在我院诊治的125例急性脑梗死患者为研究对象,采用随机数字表法分为对照组(n=62)和观察组(n=63)。对照组采用依达拉奉治疗,观察组在对照组基础上联合阿托伐他汀钙治疗,比较两组临床治疗疗效、NIHSS评分、血清hs-CRP、Hcy水平以及不良反应发生情况。结果观察组临床治疗总有效率为90.47%,高于对照组的80.64%(P<0.05);治疗后,两组NIHSS评分均低于治疗前,且观察组低于对照组(P<0.05);治疗后两组血清hs-CRP、Hcy水平均低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应发生率为6.34%,与对照组的4.83%比较,差异无统计学意义(P>0.05)。结论阿托伐他汀钙联合依达拉奉治疗急性脑梗死效果确切,可改善神经功能缺损,降低血清hs-CRP、Hcy水平,且不增加不良反应。Objective To investigate the effect of atorvastatin calcium combined with edaravone on hs-CRP and homocysteine(Hcy)levels in patients with acute cerebral infarction.Methods A total of 125 patients with acute cerebral infarction from June 2018 to June 2020 were selected as the main research object,randomly divided into control group(n=62)and observation group(n=63).The control group was treated with edaravone,the observation group was treated with atorvastatin calcium based on the treatment of the control group.The clinical curative effect,NIHSS score,serum hs-CRP,Hcy level and clinical adverse reactions were compared between the two groups.Results The total effective rate of observation group was 90.47%,which was higher than 80.64%of control group(P<0.05);after treatment,the NIHSS scores of the two groups were lower than those before treatment,and the observation group was lower than that of the control group(P<0.05);the hs-CRP、Hcy level of the two groups were lower than those before treatment,and the observation group was lower than that of the control group(P<0.05);the incidence of adverse reactions was 6.34%in the observation group,which was compared with 4.83%of the control group,with no significant difference(P>0.05).Conclusion Atorvastatin calcium combined with edaravone is effective in the treatment of acute cerebral infarction,which can significantly improve the neurological deficit,reduce the serum levels of hs-CRP and Hcy,and does not increase adverse reactions.

关 键 词：阿托伐他汀钙 依达拉奉 急性脑梗死 HS-CRP 同型半胱氨酸 

分 类 号：R743.3[医药卫生—神经病学与精神病学]